Despite efforts to develop FLT3 inhibitors, the emergence of secondary TKD mutations, such as FLT3/D835Y and FLT3/F691L limited the effectiveness of FLT3‐targeting therapies on AML patients, resulting in poor overall clinical outcomes. This evidence concerns the gene FLT3 and acute myeloid leukemia.